alexa Stem Cell Therapy for Bone and Cartilage Defects – Can Culture- expansion be Avoided? | OMICS International
ISSN: 2157-7633
Journal of Stem Cell Research & Therapy

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Stem Cell Therapy for Bone and Cartilage Defects – Can Culture- expansion be Avoided?

Elena Jones1* and Clara Sanjurjo-Rodriguez2

1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

2Rheumatology Division, INIBIC-Hospital Universitario A Coruña (CHUAC), CIBER-BBN-Cellular Therapy Area, CHUAC. Cátedra Bioibérica-University of A Coruña. A Coruña, Spain

*Corresponding Author:
Elena Jones
Leeds Institute of Rheumatic and Musculoskeletal Medicine
Room 5.24 Clinical Sciences Building, St James’s Hospital
Leeds, LS9 7TF, UK
Tel: +44 113 206 5647
E-mail: [email protected]

Received date: January 21, 2014; Accepted date: January 23, 2014; Published date: January 25, 2014

Citation: Jones E, Sanjurjo-Rodriguez C (2014) Stem Cell Therapy for Bone and Cartilage Defects – Can Culture-expansion be Avoided? J Stem Cell Res Ther 4:e118. doi:10.4172/2157-7633.1000e118

Copyright: © 2014 Jones E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Stem Cell Research & Therapy

Skeletal tissues including bone and cartilage experience significant mechanical stresses following normal physical activity. In bone, resultant microcracks are continuously repaired as a result of coordinated activity of osteoblasts, their progenitors – multipotential stromal/stem cells (MSCs) and osteoclasts, the bone-resorbing cells [1]. Physiological cartilage repair mechanisms are less well understood,but could be potentially mediated by MSCs present in cartilage superficial layer [2,3], synovium [4,5] or synovial fluid [6,7].

Significant damages to bone and cartilage can occur as a result of acute injury (trauma) or due to chronic disease (such as osteoarthritis). In acute settings, the last two decades have witnessed a significant advance in tissue engineering approaches to repair bone in cartilage, with the use of scaffolds seeded with large numbers of culture-amplified MSCs. However, more recent research has indicated that loading scaffolds with culture-expanded stem cells may not be absolutely required, and depends on the nature and size of the defect [8,9]. This Editorial will highlight recent advances in bone and cartilage repair strategies based on enhancing the recruitment of endogenous MSCs into the defect areas.

Bone Repair

Fracture is a typical example of acute injury to bone that normally repairs itself. Non-union (failure to repair) commonly occurs when bone loss is too large (a critical-size defect) or when a patient presents with co-morbidities, such as diabetes, smoking, or high blood pressure [10]. The repair of critical-size defects requires the provision of mechanical stability and the presence of sufficient numbers of MSCs and vascular progenitors at the repair site [11].

The first successful tissue-engineering constructs to repair critical size defects in humans were based on culture-expanded bone marrow MSCs seeded on macroporous hydroxyapatite scaffolds [12]. Although they were implanted over a decade ago,the uptake of this technology in general clinical practice remains low;this is most likely due to the requirement of two surgeries (for MSC harvesting and implantation), difficulties in regulating the safety of such complex cellular products and the associated high costs of therapy. Instead, a so called Ilizarov distraction/bone transfer technique remains one of the most common methods for large defect reconstruction [13]. In basic terms, it relies on stabilizing the biomechanics and reducing the distance between the bone ends, followed by a very slow and controlled ‘stretching’ thus allowing a newly-formed callus tissue to be gradually vascularized and remodeled. It is believed that in this technique, the repair cells (MSCs) originate from the neighboring tissues such as periosteum [14]. As an alternative, pieces of autograft bone, containing patient’s own MSCs and a bone scaffold, are placed inside the defect area; the remaining bone void is filled with a so called ‘graft expander’, normally a synthetic scaffold, and mechanically stabilized. Graft material can be additionally loaded with concentrated BM aspirate from the same patient in order to provide additional MSCs [8,15,16].

The success of these empirical surgical approaches suggests that even for very large bone defects culture-expanding MSCs to increase their numbers million-fold may not be necessary. Instead, the provision of correct biomechanical environment seems to be the key, coupled with a scaffold that permits colonization by neighboring tissue-resident MSCs. Potent chemokine molecules such as stromal cell-derived factor 1 (SDF-1/CXCL12) and monocyte-specific chemokine 3 (MCP-3) may facilitate further recruitment of MSCs and subsequent graft vascularization in vivo [17-19]. Similar strategies based on manipulating resident MSCs for cartilage tissue regeneration are illustrated below.

Cartilage Repair

It is well-recognized that cartilage repair critically depends on the depth of a defect; full-thickness (osteochondral) defects that penetrate into the subchondral bone repair much better than partial-thickness (chondral) defects that commonly fail to repair [20]. This difference can be explained by larger numbers of MSCs present in subchondral bone [21,22] as opposed to their relative paucity in cartilage [2,3] or synovial fluid [6,7]. A surgical procedure called microfracture remains the gold standard for the treatment of isolated cartilage defects [23]; in this technique drilling into the subchondral bone plate creates a blood clot that is believed to have two valuable functions: first, it serves as a source of chemokines bringing subchondral bone MSCs to the repair site and second, it acts as a fibrin-based natural scaffold allowing retention, proliferation and chondrogenic differentiation of migrated MSCs [22].

Although it is generally assumed that MSCs residing in subchondral bone cavities are chiefly responsible for cartilage repair following microfracture, other joint-resident MSCs as synovium MSCs [5], synovial fluid MSCs [24] or superficial cartilage MSCs [2,3] could be also involved, particularly since these MSC types are known to possess high chondrogenic potentials [24,25] and to have a direct access to cartilage. Recently, Sharma et al. [26] detected the presence of synovial fluid in the defect areas three weeks after implantation of empty hydrogel-based scaffolds, combined with microfracture, in fifteen patients with isolated cartilage lesions. MSCs injected into the joint space have been found in regenerated cartilage and meniscus [27], proving that these MSC could migrate through the fluid and reach the damaged areas of cartilage. Finally, the penetration of host cells into the defect site, ‘assumedly from the surrounding marrow and/or synovial spaces’, has been eloquently shown in Quintavalla et al. study [28].

How these endogenous MSCs are recruited into cartilage defects remains unclear. In a case of microfracture, a passive release of MSCs from the subchondral bone or the bone marrow is possible; however it is likely to be followed by their active migration driven by a simultaneous release of potent chemokine molecules into the synovial fluid [29]. Recently, several chemokines present in the synovial fluid, such as CCL25, CXCL10 and XCL1 were implicated in these migration processes [30]. Platelet-derived growth factors (PDGFs),concentrated inside the fibrin clot [31] and shown to chemotaxic for MSCs [32], could be also involved. These PDGFs could influence MSC migration, as well as their subsequent proliferation [33], differentiation and matrix synthesis.

It can be envisaged that in principle, similar MSC migration mechanisms could be re-created with the use of ‘smart’ scaffolds placed in the defect site. In order to develop these new approaches, a better knowledge of the types of chemokines and their corresponding receptors on the surface of different types of MSCs is needed. For example, implantation of scaffolds loaded with TGFß3 has led to excellent repair, by endogenous cell homing, in a rabbit model [34]. Migration of human synovial MSCs and their infiltration into similar scaffolds was improved with the creation of a stable gradient of SDF-1/CXCL12 [35]. The most recent work from the same laboratory has highlighted ‘the need to test multiple cytokines concurrently due to synergistic or antagonistic effects’ [36].

MSCs from different tissues possess different migration potentials towards the same chemokine because they express different patterns of the corresponding chemokine receptors [37-39]. Cultured MSCs lose a full repertoire of their chemokine receptors after extensive passaging [37]. Further work is therefore needed to isolate uncultured MSCs from the joint tissues, such as synovium, and to investigate their chemokine receptor expression and the chemokine responsiveness prior to in vitro culture. This knowledge would help to design novel scaffolds, loaded with specific chemokines, in order to attract endogenous MSCs intothe sites of cartilage damage.


Recent evidence suggests that manipulating the migration of endogenous MSCs from tissues surrounding bone or cartilage defects could represent a viable alternative to traditional tissue engineering approaches with scaffolds seeded with culture-expanded MSCs. Further work is needed to better understand the in vivo signaling mechanisms responsible for physiological chemokine releases post-injury [40] as well as to study the cellular interactions between migrated MSCs and other cells resident in damaged tissues [41].


Clara Sanjurjo-Rodriguez is beneficiary of an Erasmus fellowship from University A Coruna (Spain).


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 4th International Conference on Bioscience July 2-3, 2018 Vienna, Austria
    July 2-3, 2018 Vienna, Austria
  • 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand
    April 16-18, 2018 Amsterdam, Netherlands
  • 9th International Conference on Tissue Science and Regenerative Medicine July 13-14, 2018 Sydney, Australia
    April 23-24, 2018 Las Vegas, USA
  • 10th Annual Conference on Stem Cell and Regenerative Medicine August 13-14, 2018 London, UK
    August 13-14, 2018 London, UK
  • World Congress on Stem Cell Biology and Biobanking September 3-4, 2018 Tokyo, Japan
    September 3-4, 2018 Tokyo, Japan
  • 2nd Annual summit on Cell Metabolism and Cytopathology September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 2nd Annual summit on Cell Signaling and Cancer Therapy September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 6th Annual Congress on Biology and Medicine of Molecules September 20-21,2018 Kuala Lumpur, Malaysia
    September 20-21,2018 Kualalumpur, Malaysia
  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, Pennsylvania, USA
    September 21-22,2018 Philadelphia, USA
  • 11th International Conference on Genomics and Pharmacogenomics September 21-22, 2018 Philadelphia, Pennsylvania, USA
    September 21-22, 2018 Philadelphia, USA
  • 5th World Congress on HUMAN GENETICS SEPTEMBER 24-25, 2018 BERLIN, GERMANY
    SEPTEMBER 24-25, 2018 Berlin, Germany
  • 21st Euro Biotechnology Congress October 11-12, 2018 Moscow, Russia
    October 11-12, 2018 Moscow, Russia
  • 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy
    October 18-20, 2018 Rome, Italy
  • 24th Biotechnology Congress: Research & Innovations October 24-25, 2018 Boston, USA
    October 24-25, 2018 Boston, USA
  • International Conference on Human Genome Meeting October 25-26, 2018 Istanbul, Turkey
    October 25-26, 2018 Istanbul, Turkey
  • International Congress & Expo on Genomics and Bioinformatics November 2-3, 2018 Columbus, Ohio, USA
    November 2-3, 2018 Columbus, USA
  • 12th International Conference & Exhibition on Tissue Preservation and Biobanking November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA
  • 2nd Annual Summit on Cell Therapy and Stem Cell Research November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA

Article Usage

  • Total views: 11925
  • [From(publication date):
    January-2014 - Jun 18, 2018]
  • Breakdown by view type
  • HTML page views : 8134
  • PDF downloads : 3791

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7